ScreenerHero

RDHLRedHill Biopharma Ltd.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · redhillbio.com
0.6300USDMkt Cap: 3.83M $P/E: Infinity

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in ad…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap3.83M $
Enterprise Value281.96K $
Revenue (TTM)286.00K $
Gross Profit286.00K $
Net Income (TTM)-429.00K $
Revenue/Share0.0910 USD
Last Price0.6300 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)Infinity
P/E (Forward)20.83
PEG—
EV/EBITDA-0.04
EV/Revenue0.99
P/S13.29
P/B0.75
EPS (TTM)0.00
EPS (Forward)0.03
52W Range
0.600060% of range0.6500
52W High0.6500 USD
52W Low0.6000 USD
Profitability
Gross Margin100.00%
Oper. Margin-2765.38%
EBITDA Margin0.00%
Profit Margin-150.00%
ROE-10.05%
ROA-1.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.65M $
CapEx (TTM)5.00K $
FCF Margin-760.84%
FCF Yield-56.80%
Net Debt-2.90M $
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity0.25
Current Ratio0.34
Quick Ratio0.29
Book Value/Sh0.8380 USD
Cash/Share0.7800 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 20, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.08M
Float4.20M
Insiders0.00%
Institutions5.19%
Short Interest
Short Ratio0.5d
Short % Float0.50%
Short % Out.0.49%
Shares Short29.93K
Short (prev mo.)31.15K
Technical
SMA 500.7266 (-13.3%)
SMA 2000.9640 (-34.6%)
Beta4.90
S&P 52W Chg21.00%
Avg Vol (30d)19.42K
Avg Vol (10d)32.37K
Technical Indicators
RSI (14)45.9
MACD-0.0314
MACD Signal-0.0406
MACD Hist.+0.0092
BB Upper0.7132 USD
BB Middle0.6288 USD
BB Lower0.5443 USD
BB Width26.86%
ATR (14)0.0530 USD
Vol Ratio (20d)0.52x